Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...
The following content is for informational purposes only. This article is not intended to be a substitute for profession ...
Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...
The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.
Intramuscular fat, contained within muscle tissue, increases the risk of serious heart disease, regardless of other risk factors, a new study suggests.
Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Vendors such as Color Health promise to save employers money by helping workers catch cancer sooner, but these initiatives ...
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...